CMS: Medicaid should cover Aduhelm as outpatient drug


State Medicaid programs should cover Biogen and Eisai's Alzheimer's disease drug Aduhelm as an outpatient drug, said John Coster, director of pharmacy at CMS' Center for Medicaid and CHIP Services. Speaking at AHIP's National Conference on Medicare, Medicaid & Dual Eligibles, Coster said Biogen is part of Medicaid's drug rebate program, though states can create criteria for treatment eligibility.

Full story:

FDLI SmartBrief

The latest regulatory and company news on food, drugs, animal drugs, biologics, cosmetics, diagnostics, dietary supplements, medical devices and tobacco

Designed specifically for professionals involved in the food and drug law community, FDLI SmartBrief is a FREE daily e-mail newsletter. It provides the latest need-to-know news and industry information that maximizes your time, giving you an edge over your competition.